Valuation: Genix Pharmaceuticals Corporation

Market Cap 918K 658K 571K 534K 488K 62.77M 934K 6.25M 2.45M 31.45M 2.47M 2.42M 105M P/E 2024
-40.5x
P/E 2025 -5.33x
Enterprise Value 1.92M 1.37M 1.19M 1.11M 1.02M 131M 1.95M 13.06M 5.12M 65.67M 5.17M 5.05M 219M EV / Sales 2024
929,496,174x
EV / Sales 2025 -
Free-Float
53.08%
Yield 2024 *
-
Yield 2025 -
1 day-8.61%
3 months-2.13%
6 months-2.13%
Current year-54.00%
Current year 0.01
Extreme 0.0138
0.02
1 year 0.01
Extreme 0.0138
0.04
3 years 0.01
Extreme 0.0138
0.05
5 years 0.01
Extreme 0.007
0.25
10 years 0
Extreme 0.0001
0.25
Manager TitleAgeSince
Chief Executive Officer 57 2018-08-02
President - 2021-05-20
Director of Finance/CFO - 2020-12-13
Director TitleAgeSince
Director/Board Member 57 2018-08-02
Director/Board Member 76 2019-03-10
Director/Board Member 44 2019-09-04
Change 5-day change 1-year change 3-year change Capi.($)
-8.61%-.--% - - 659K
-0.03%-2.32%+22.53%+68.67% 49.03B
-1.14%+13.15%+60.80%+127.29% 42.33B
+0.27%-0.37%-1.22%+15.93% 12.43B
+0.43%-0.69%+19.53%+69.15% 11.68B
-0.19%+0.19%+30.98%+140.74% 9.12B
+3.81%+8.39%+22.04%+39.32% 7.15B
+1.62%+1.47%+41.67%-12.77% 7.09B
-1.22%+0.78%+11.47%+171.70% 6.76B
+0.03%+8.29%-24.59%+28.71% 5.95B
Average -0.50%+2.39%+20.36%+72.08% 16.84B
Weighted average by Cap. -0.08%+1.73%+30.08%+82.92%

Financials

2024 2025
Net sales 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.46 -
Net income -73.2K -52.47K -45.5K -42.53K -38.88K -5M -74.44K -498K -195K -2.51M -197K -193K -8.36M -335K -240K -208K -195K -178K -22.9M -341K -2.28M -894K -11.47M -903K -883K -38.28M
Net Debt 804K 577K 500K 467K 427K 54.97M 818K 5.48M 2.15M 27.54M 2.17M 2.12M 91.87M 999K 716K 621K 581K 531K 68.31M 1.02M 6.8M 2.67M 34.22M 2.69M 2.63M 114M
Logo Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation is a Canadian ophthalmic drugs company. The Company is a formulator, manufacturer, licensor and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its operations consist primarily of the research, development, manufacture, in-licensing and sales of novel and healthcare products, focusing on proprietary over the counter (OTC) nutraceuticals and generic pharmaceuticals. The Company has been marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Timolol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Moxifloxacin Hydrochloride 0.5% Eye Drops, Prednisolone Acetate 1% Eye Drops, Olopatadine 0.1% Eye Drops, and others.
Employees
4,000